Nephrotoxicity of recent anti-cancer agents

被引：75
作者：
Lameire, Norbert [1 ]
机构：
[1] Univ Hosp, 185 Pintelaan, B-9000 Ghent, Belgium
来源：
CLINICAL KIDNEY JOURNAL | 2014年 / 7卷 / 01期
关键词：
anti-angiogenesis drugs and cancer; anti-cancer drugs and nephrotoxicity; androgen deprivation therapy and AKI;
D O I：
10.1093/ckj/sft135
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Cancer patients may develop a variety of kidney lesions that impair not only their immediate survival but also limit the adequate treatment of the underlying malignant process. This review summarizes the nephrotoxic potential of some of the most recently developed anti-cancer drugs, focusing on those interfering with the vascular endothelial growth factor and epidermal growth factor receptor pathways and mammalian target of rapamycin inhibitors. Thrombotic microangiopathy (haemolytic-uraemic syndrome), proteinuria, hypertension and magnesium depletion are the most common side effects. Also the risk for developing acute kidney injury in patients with advanced prostate cancer undergoing androgen deprivation therapy is discussed.
引用
收藏
页码：11 / 22
页数：12
相关论文
共 112 条
[21]   Biology of Anti-Angiogenic Therapy-Induced Thrombotic Microangiopathy [J].
Eremina, Vera ;
Quaggin, Susan E. .
SEMINARS IN NEPHROLOGY, 2010, 30 (06) :582-590
[22]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[23]  
Fakih M, 2008, ONCOLOGY-NY, V22, P74
[24]   Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine [J].
Flombaum, CD ;
Mouradian, JA ;
Casper, ES ;
Erlandson, RA ;
Benedetti, F .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (03) :555-562
[25]  
Fung MC, 1999, CANCER-AM CANCER SOC, V85, P2023
[26]  
Glezerman I, 2009, CLIN NEPHROL, V71, P130
[27]   MUTATIONS OF THE VHL TUMOR-SUPPRESSOR GENE IN RENAL-CARCINOMA [J].
GNARRA, JR ;
TORY, K ;
WENG, Y ;
SCHMIDT, L ;
WEI, MH ;
LI, H ;
LATIF, F ;
LIU, S ;
CHEN, F ;
DUH, FM ;
LUBENSKY, I ;
DUAN, DR ;
FLORENCE, C ;
POZZATTI, R ;
WALTHER, MM ;
BANDER, NH ;
GROSSMAN, HB ;
BRAUCH, H ;
POMER, S ;
BROOKS, JD ;
ISAACS, WB ;
LERMAN, MI ;
ZBAR, B ;
LINEHAN, WM .
NATURE GENETICS, 1994, 7 (01) :85-90
[28]   Is Therapeutic Plasma Exchange Indicated for Patients with Gemcitabine-Induced Hemolytic Uremic Syndrome? [J].
Gore, Ethan McCaleb ;
Jones, Benjamin Scott ;
Marques, Marisa B. .
JOURNAL OF CLINICAL APHERESIS, 2009, 24 (05) :209-214
[29]   Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? [J].
Gotink, Kristy J. ;
Verheul, Henk M. W. .
ANGIOGENESIS, 2010, 13 (01) :1-14
[30]   Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab [J].
Gourley, Brett L. ;
Mesa, Hector ;
Gupta, Pankaj .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (05) :1001-1004
12345678910